Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

A new pill that ‘slows down Alzheimer's' is being considered for use in the NHS. Developed by a small British firm in Aberdeen called TauRX Hydromethylthionine mesylate (HMTM) is a daily pill ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

It raises the prospect of it being the third successive drug in a new era of Alzheimer’s treatments to not be approved for NHS patients amid concerns that Nice’s cost assessments of the ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

A potentially 'game-changing' drug that could slow the progression ... hailed the trial results as "great news for people with Alzheimer's disease, their families and carers." ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...